Compared with the 6-month pre-treatment period (before the first injection of dupilumab), the median number of asthma exacerbations dramatically decreased from 4.0 (2.0-5.0) to 0.0 (0.0-0.0) (p < 0.0001) after 6 months of anti-IL4R/IL-13R therapy (Figure 1A). Here, IL13RA1 is linked to asthma.